CN116473903A - 一种保湿舒缓修护的高功效婴童护肤精华液及制备方法 - Google Patents
一种保湿舒缓修护的高功效婴童护肤精华液及制备方法 Download PDFInfo
- Publication number
- CN116473903A CN116473903A CN202310500647.XA CN202310500647A CN116473903A CN 116473903 A CN116473903 A CN 116473903A CN 202310500647 A CN202310500647 A CN 202310500647A CN 116473903 A CN116473903 A CN 116473903A
- Authority
- CN
- China
- Prior art keywords
- skin
- oil
- essence
- parts
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000003906 humectant Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000003921 oil Substances 0.000 claims description 20
- 235000019198 oils Nutrition 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 15
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 10
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 10
- VKIJBOMCWLTQBD-UHFFFAOYSA-N benzoic acid N-(2-hydroxyphenyl)propanamide Chemical compound C(C1=CC=CC=C1)(=O)O.C(CC)(=O)NC1=C(C=CC=C1)O VKIJBOMCWLTQBD-UHFFFAOYSA-N 0.000 claims description 9
- 210000002969 egg yolk Anatomy 0.000 claims description 9
- 239000000419 plant extract Substances 0.000 claims description 9
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 8
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 8
- 102000002322 Egg Proteins Human genes 0.000 claims description 8
- 108010000912 Egg Proteins Proteins 0.000 claims description 8
- 244000258095 Salvia lavandulifolia Species 0.000 claims description 8
- 235000001500 Salvia lavandulifolia Nutrition 0.000 claims description 8
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 8
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 8
- 229940036350 bisabolol Drugs 0.000 claims description 8
- 229940012466 egg shell membrane Drugs 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 7
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 7
- 229940071160 cocoate Drugs 0.000 claims description 7
- 235000013345 egg yolk Nutrition 0.000 claims description 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 7
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229930004725 sesquiterpene Natural products 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- 230000003750 conditioning effect Effects 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims description 4
- 239000008168 almond oil Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 235000002020 sage Nutrition 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 claims description 2
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 claims description 2
- 239000001306 (7E,9E,11E,13E)-pentadeca-7,9,11,13-tetraen-1-ol Substances 0.000 claims description 2
- INIOTLARNNSXAE-UHFFFAOYSA-N 4,8-dimethyl-2-propan-2-ylidene-3,3a,4,5,6,8a-hexahydro-1h-azulen-6-ol Chemical compound CC1CC(O)C=C(C)C2CC(=C(C)C)CC12 INIOTLARNNSXAE-UHFFFAOYSA-N 0.000 claims description 2
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 239000004264 Petrolatum Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229940059958 centella asiatica extract Drugs 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 238000007599 discharging Methods 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 229930002886 farnesol Natural products 0.000 claims description 2
- 229940043259 farnesol Drugs 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000008169 grapeseed oil Substances 0.000 claims description 2
- 229940119170 jojoba wax Drugs 0.000 claims description 2
- 229940066842 petrolatum Drugs 0.000 claims description 2
- 235000019271 petrolatum Nutrition 0.000 claims description 2
- -1 sesquiterpene alcohols Chemical class 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 5
- 240000007164 Salvia officinalis Species 0.000 claims 1
- 235000002912 Salvia officinalis Nutrition 0.000 claims 1
- 210000003278 egg shell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229940064064 purslane extract Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 5
- 239000013011 aqueous formulation Substances 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 88
- 238000012360 testing method Methods 0.000 description 54
- 230000000694 effects Effects 0.000 description 22
- 239000000523 sample Substances 0.000 description 17
- 239000004519 grease Substances 0.000 description 14
- 230000008859 change Effects 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 240000005481 Salvia hispanica Species 0.000 description 9
- 235000001498 Salvia hispanica Nutrition 0.000 description 9
- 206010015150 Erythema Diseases 0.000 description 7
- 150000003278 haem Chemical class 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000036572 transepidermal water loss Effects 0.000 description 7
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 6
- 229920002498 Beta-glucan Polymers 0.000 description 6
- 102000004125 Interleukin-1alpha Human genes 0.000 description 6
- 108010082786 Interleukin-1alpha Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 229960002986 dinoprostone Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 206010034972 Photosensitivity reaction Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 206010040914 Skin reaction Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 3
- 208000007578 phototoxic dermatitis Diseases 0.000 description 3
- 231100000018 phototoxicity Toxicity 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940015975 1,2-hexanediol Drugs 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 244000146462 Centella asiatica Species 0.000 description 2
- 235000004032 Centella asiatica Nutrition 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 244000234609 Portulaca oleracea Species 0.000 description 2
- 235000001855 Portulaca oleracea Nutrition 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011164 primary particle Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000010181 skin prick test Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000009602 toxicology test Methods 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种保湿舒缓修护的高功效婴童护肤精华液,按质量份计,制备原料包括:0.5‑3份舒缓组合物、5‑12份保湿剂、0.1‑1份乳化剂、0.1‑0.8份肤感调理剂、85‑120份水。本发明中精华液含水90%以上,甘油含量2%,依靠合理优异的功效物搭配,达到了超高功效,拓宽了婴童市场产品开发思路,展现了水剂剂型在婴童功效化妆品上的开发潜力。
Description
技术领域
本发明涉及A61K8/98领域,更具体涉及一种保湿舒缓修护的高功效婴童护肤精华液及制备方法。
背景技术
婴幼儿皮肤具有与成人不同的生理特点,婴幼儿皮肤较成人角质层薄、皮肤屏障功能不全、易干燥易敏感。目前市场上婴童产品普遍需求功效:保湿、舒缓、修护,能达到以上功效需求的品类以高封闭性油脂含量的厚重面霜为主。精华品类由于其水剂结构特性,在成人护理领域应用成熟,在婴童开发较少。
CN114939090A公开了一种抗敏舒缓修复配方的组合物,原料包括:甘草提取物、白花春黄菊花提取物、积雪草提取物、虎杖提取物、燕麦提取物、丁二醇和对羟基苯乙酮,通过将具有抗炎、舒缓抗敏等功效的植物提取物混合,共同作用实现止痒褪红和抗敏修复效果,但提高效果不显著,并且高含量活性物添加的化妆品易产生刺激性及致敏。
CN108542870B公开了一种温和舒缓婴幼儿面霜,面霜包含以下组分:保湿剂、润肤剂、乳化剂、增稠剂、牛奶精华、甜扁桃油、泛醇等成分,牛奶为肌肤提供封闭性油脂,在皮肤表面形成薄膜防止水分流失,温和呵护宝宝娇嫩肌肤,令宝宝肌肤健康水润。精华相较于面霜更易铺展、吸收,但封闭性较低,精华水剂结构难以在保证其婴幼儿可用的安全性的同时做到很高的保湿舒缓效果,因此,市面上缺少婴幼儿可用的安全性强、且高功效(高保湿、高舒缓)的精华护肤技术。
发明内容
针对于上述问题,本发明公开了一种保湿舒缓修护的高功效婴童护肤精华液,按质量份计,制备原料包括:0.5-3份舒缓组合物、5-12份保湿剂、0.1-1份乳化剂、0.1-0.8份肤感调理剂、85-120份水。
在一种实施方式中,所述舒缓组合物选自植物提取物、天然油脂、倍半萜烯醇、水解蛋壳膜、羟苯基丙酰胺苯甲酸、维生素C及其衍生物中的一种多种。
优选的,所述舒缓组合物为植物提取物、天然油脂、倍半萜烯醇、水解蛋壳膜和羟苯基丙酰胺苯甲酸的组合,质量比为(0.001-30):(0.001-20):(0.0005-2):(0.00005-2):(0.0005-5)。
在一种实施方式中,所述植物提取物选自西班牙鼠尾草(SALVIAHISPANICA)籽提取物、甘草酸二钾、积雪草(Centellaasiatica)提取物、马齿苋(Portulacaoleracea)提取物中的一种或多种。
优选的,所述植物提取物为西班牙鼠尾草(SALVIAHISPANICA)籽提取物和甘草酸二钾的组合,质量比为(0.05-3):(0.1-7)。
进一步优选的,所述植物提取物为西班牙鼠尾草(SALVIAHISPANICA)籽提取物和甘草酸二钾的组合,质量比为(0.05-2):(3-6)。
更优选的,所述植物提取物为西班牙鼠尾草(SALVIAHISPANICA)籽提取物和甘草酸二钾的组合,质量比为0.1:5。
在一种实施方式中,所述天然油脂选自蛋黄油、鱼油、蓖麻油、椰子油、杏仁油、葡萄籽油、荷荷巴油中的一种或多种。
优选的,所述天然油脂为蛋黄油。
在一种实施方式中,所述倍半萜烯醇选自檀香醇、红没药醇、岩兰草醇、金合欢醇中的一种或多种。
优选的,所述倍半萜烯醇为红没药醇。
本发明中使用的蛋黄油、红没药醇、西班牙鼠尾草(SALVIAHISPANICA)籽提取物、甘草酸二钾、蛋壳膜、羟苯基丙酰胺苯甲酸共同作用下,实现对肌肤的舒缓功能。
在一种实施方式中,所述保湿剂选自醇类、氨基酸、糖类、矿脂中的一种或多种。
优选的,所述保湿剂为醇类、氨基酸、糖类的组合,质量比(5-8):(1-2.5):(0.005-2)。
在一种实施方式中,所述醇类选自甘油、丁二醇、双丙甘醇、丙二醇、1,2-戊二醇、已二醇、木糖醇、聚丙二醇、山梨糖醇中的一种或多种。
优选的,所述醇类为双丙甘醇、甘油、1,2-戊二醇、丁二醇的组合,质量比为(2-4):(1.5-3):(0.05-1):(0.03-0.8)。
在一种实施方式中,所述氨基酸选自甜菜碱、精氨酸、丝氨酸、亮氨酸、谷氨酸中的一种或多种。
优选的,所述氨基酸为甜菜碱、精氨酸、丝氨酸的组合,质量比为(1-2):(0.1-1):(0.05-0.8)。
在一种实施方式中,所述糖类选自α-葡聚糖、β-葡聚糖、海藻糖、燕麦多糖、银耳多糖中的一种或多种。
优选的,所述糖类为β-葡聚糖。
在一种实施方式中,所述乳化剂为低分子表面活性剂和/或高分子表面活性剂。
优选的,所述高分子表面活性剂为丙烯酸类聚合物。
进一步优选的,所述丙烯酸类聚合物丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物。
在一种实施方式中,所述肤感调理剂选自油脂、淀粉、植物多糖中的一种或多种。
优选的,所述肤感调理剂为油脂。
进一步优选的,所述油脂为辛酸/癸酸甘油三酯、PEG-7甘油椰油酸酯、抗坏血酸棕榈酸酯的组合,质量比为(0.001-2):(0.001-2):(0.00005-2)。
本发明选用肤感调理剂为油脂,当油脂为油溶性油脂辛酸/癸酸甘油三酯、抗坏血酸棕榈酸酯与水溶性油脂的PEG-7甘油椰油酸酯、的组合,质量比满足要求时,不仅可以改善肤感,还可以与乳化剂共同形成悬浮稳定油脂体系,从而避免高含量的乳化剂残留对皮肤的影响,本配方采用了聚合物乳化技术“丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物”作为乳化剂,乳液遇到皮肤会迅速释放油相,保证油相舒缓活性物的快速和充分渗透;另外,乳液涂抹后不会遇水再次乳化,使得功效物和润肤剂可以较长时间停留在皮肤上;此聚合物类乳化剂分子量大且用量低(原始粒子平均分子量约为几十亿道尔顿),相较于常规的分子量更小的水包油乳化剂,对于皮肤刺激性更小更安全。
在一种实施方式中,按质量份计,制备原料还包括:0.8-1.5份防腐剂、0.05-0.5份增稠剂。
优选的,所述防腐剂包括但不限于对羟基苯乙酮、1,2-己二醇、戊二醇、乙基己基甘油中的一种或多种。所述增稠剂包括但不限于黄原胶、聚丙烯酸钠、丙烯酸酯类共聚物、卡波姆中的一种或多种。本领域技术人员依据实际需求选择即可。
本发明采用了精简配方,减少了潜在对皮肤有刺激的物质的风险。本配方全成分22个,其中基础成分数量10个,功效成分数量12个,切实做到不添加任何不必要成分,使每个成分都充分发挥其在配方中、在皮肤上的作用。本发明精华液含有自主研发的专利蛋黄油组合物(CN115804735A)以及其他功效组合成分,在3D皮肤模型上具有堪比阳性对照的保湿、舒缓、修护功效;在人体测试使用后30分钟,连续使用14天,均具有显著性的保湿、舒缓、修护功效。该精华液含水90%以上,甘油含量2%,依靠合理优异的功效物搭配,达到了超高功效,拓宽了婴童市场产品开发思路,展现了水剂剂型在婴童功效化妆品上的开发潜力。
本精华液已通过化妆品毒理测试(急性眼刺激试验、多次皮肤刺激性试验、皮肤变态反应试验、皮肤光毒性试验)、斑贴试验,证明在高功效的同时还保证了高安全性,婴童可以放心使用。
本精华液已通过稳定性测试,证明在高功效的同时还保证了其配方稳定性。
本发明另一方面公开了所述精华液的制备方法,包括以下步骤:常温下将水加入水锅,撒入乳化剂,分散至均匀,然后加入醇类、增稠剂搅拌加热至80-85℃,搅拌至物料完全溶解后开启降温,降温至40-50℃时,加入氨基酸、甘草酸二钾,搅拌至料体均一;开启均质,加入蛋黄油、红没药醇、辛酸/癸酸甘油三酯,3000-4000r均质4-6min,搅拌至料体均一;加入糖类保湿剂、西班牙鼠尾草(SALVIAHISPANICA)籽提取物、水解蛋壳膜、羟苯基丙酰胺苯甲酸、抗坏血酸棕榈酸酯、PEG-7甘油椰油酸酯、防腐剂搅拌均匀,真空脱泡,搅拌冷却至38±2℃,取料检验理化指标,合格后300目滤布过滤出料。
有益效果
1、本发明中使用的蛋黄油、红没药醇、西班牙鼠尾草(SALVIAHISPANICA)籽提取物、甘草酸二钾、蛋壳膜、羟苯基丙酰胺苯甲酸共同作用下,实现对肌肤的舒缓功能。
2、肤感调理剂为油脂,所述油脂为油溶性油脂辛酸/癸酸甘油三酯、抗坏血酸棕榈酸酯与水溶性油脂的PEG-7甘油椰油酸酯的组合,质量比满足要求时,还可以与乳化剂共同形成悬浮稳定油脂体系,从而避免高含量的乳化剂残留对皮肤的影响。
3、聚合物类乳化剂分子量大且用量低(原始粒子平均分子量约为几十亿道尔顿),相较于常规的分子量更小的水包油乳化剂,对于皮肤刺激性更小更安全。
4、本发明采用了精简配方,减少了潜在对皮肤有刺激的物质的风险。
5、保湿剂中的丝氨酸、精氨酸和甜菜碱,保湿效果好,不油腻。
6、多功效β-葡聚糖,奠定屏障修护力的同时升华整个配方保湿、舒缓的功效力,与其他功效组分融为一体,共同增效。
7、本发明精华液含有的蛋黄油组合物,以及其他功效组合成分,在3D皮肤模型上具有堪比阳性对照的保湿、舒缓、修护功效;在人体测试使用后30分钟,连续使用14天,均具有显著性的保湿、舒缓、修护功效。
8、该精华液含水90%以上,甘油含量2%,依靠合理优异的功效物搭配,达到了超高功效,拓宽了婴童市场产品开发思路,展现了水剂剂型在婴童功效化妆品上的开发潜力。
附图说明
图1实施例1皮肤红区a值结果图
图2实施例1皮肤红区a值变化率结果图
图3实施例1皮肤红区面积占比结果图
图4实施例1皮肤红区面积占比的变化率结果图
图5实施例1皮肤血红素含量结果图
图6实施例1皮肤血红素含量变化率结果图
图7实施例1皮肤颜色L*值结果图
图8实施例1皮肤颜色L*值变化率结果图
图9实施例1皮肤颜色a*值结果图
图10实施例1皮肤颜色a*值变化率结果图
图11实施例1皮肤角质层水分含量结果图
图12实施例1皮肤角质层水分含量变化率结果图
图13实施例1皮肤经皮水分流失率结果图
图14实施例1皮肤经皮水分流失率变化率结果图
图15实施例1第27号受试者VISIA CR标准光源1采集图像
图16实施例1第27号受试者VISIA CR RBX红区图采集图像
具体实施方式
实施例1
本实施例1公开了一种保湿舒缓修护的高功效婴童护肤精华液,按质量份计,原料见下表1。
表1
所述丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物购自于Lubrizol AdvancedMaterials,Inc。
所述蛋黄油购自于江苏泰富源生物科技有限公司。
所述β-葡聚糖购自于HYUNDAI BIOLAND CO.,LTD。
所述羟苯基丙酰胺苯甲酸购自于德之馨香精香料(南通)有限公司。
所述西班牙鼠尾草(SALVIAHISPANICA)籽提取物购自于Signum Biosciences,Inc。
所述水解蛋壳膜购自于Kewpie Corporation。
本实施例1另一方面公开了所述精华液的制备方法,步骤如下:常温下将水加入水锅,撒入丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物,分散至均匀,然后加入醇类保湿剂、黄原胶搅拌加热至82℃,搅拌至物料完全溶解后开启降温,降温至45℃时,加入甜菜碱、精氨酸、丝氨酸、甘草酸二钾,搅拌至料体均一;开启均质,加入蛋黄油、红没药醇、辛酸/癸酸甘油三酯,3500r均质5min,搅拌至料体均一;加入β-葡聚糖、西班牙鼠尾草(SALVIAHISPANICA)籽提取物、水解蛋壳膜、羟苯基丙酰胺苯甲酸、抗坏血酸棕榈酸酯、PEG-7甘油椰油酸酯、1,2-己二醇、对羟基苯乙酮搅拌均匀,真空脱泡,搅拌冷却至38℃,300目滤布过滤出料,即可。
性能测试
1、精华液毒理测试
(1)急性眼刺激性试验:在不冲洗条件下,为无刺激性。
受试物对家兔急性眼刺激性试验结果
不冲洗
(2)多次皮肤刺激性试验:无刺激性。
受试物对家兔多次皮肤刺激性试验结果
(3)皮肤变态反应试验:未见皮肤变态反应。
注:①起始体重、终止体重的表示方式为均值±SD。
②在皮肤反应强度栏中应填写当皮肤反应积分为0、1、2、3…时,发生反应的动物数占受试动物数的比例。
(4)皮肤光毒性试验:未见皮肤光毒性。
2、精华液斑贴测试
选取30名受试者参加测试,测试结果均判定有效。在去除受试物斑试器后30分钟、24小时和48小时由皮肤科医生检查样品区和对照区的皮肤反应,结果全部为阴性。
样品浓度:样品原物
对照:空白斑试器
3、精华液3D皮肤模型功效测试
(1)保湿功效
①测试原理:本测试采用600mJ/cm2UVB刺激3D表皮皮肤模型采用表面给药的方式,通过给药后观测表皮皮肤模型的皮肤含水量的变化,评估待测样品的保湿功效。皮肤接触刺激性因素时,会导致皮肤屏障发生临床性的急性损伤,导致皮肤干燥现象。皮肤含水量是决定皮肤健康状态的主要指标,也是评价与水分丢失相关的皮肤状态的重要参数,保湿护肤剂可保持皮肤表面的水分,使皮肤表面滋润,可增加皮肤表面的电容。其电容值越高,表明皮肤角质层含水量越高。因此,可以通过给药后表皮皮肤模型的皮肤含水量的变化,评价待测物的保湿功效
②测试系统:本测试所用3D表皮皮肤模型批号:ES230101,由广东博溪生物科技有限公司提供。EpiGrowth培养液(广东博溪生物)、PBS(索莱宝)、甘油(国药)。CO2培养箱(Thermo,150I)、超净工作台(苏州安泰,SW-CJ-1F)、UVB照射仪(飞利浦)、CM825皮肤含水量测试仪(Courage+Khazakaelectronic)。
③测试分组及结果
与BC组相比,NC组的皮肤含水量显著下降,说明本次测试刺激条件有效。
与NC组相比,PC组的皮肤含水量显著上升,说明本次测试阳性对照有效。
与NC组相比,样品精华液的皮肤含水量显著上升,提升率为205.71%。
(2)舒缓功效
①测试原理:本测试采用600mJ/cm2UVB刺激3D表皮皮肤模型通过检测样品作用后炎症因子(IL-1α、TNF-α)以及炎性介质(PGE2)含量的变化,评价待测样品的舒缓功效。短波紫外线照射皮肤后,导致活细胞释放大量的炎症因子,介导炎症级联反应,从而导致皮肤出现发红等临床炎症现象。IL-1α为无疏水性的多肽,细胞膜损伤后会释放到细胞外。待测物作用后IL-1α含量降低说明具有舒缓的功效。TNF-α为含有疏水性末端的多肽,炎症相关通路激活后可以分泌到细胞外。待测物作用后TNF-α含量降低,说明具有舒缓的功效。PGE2为前列腺素,是花生四烯酸代谢产物,主要作用是诱发炎症反应,待测物作用后PGE2含量减少,可以达到舒缓的功效。因此,本测试以3D表皮皮肤模型/>为研究对象,采用UVB照射建立体外损伤模型,通过检测炎症因子(IL-1α、TNF-α)以及炎性介质(PGE2)含量的变化来分析待测化合物的舒缓功效。
②测试系统:本测试所用模型为3D表皮皮肤模型批号为:ES230101,由广东博溪生物科技有限公司提供。主要试剂EpiGrowth培养液(广东博溪生物)、PBS(索莱宝)、IL-1αELISA试剂盒(Abcam)、PGE2ELISA试剂盒(Abcam)、TNF-αELISA试剂盒(Abcam)、地塞米松(中检所)。主要设备CO2培养箱(Thermo,150i)、超净工作台(苏州安泰,SW-CJ-1F)、酶标仪(BioTek,Epoch)、UVB照射仪(飞利浦)。
③测试分组及结果
IL-1α测试结果
与BC组相比,NC组的IL-1α含量显著上升,说明本次测试刺激条件有效。
与NC组相比,PC组的IL-1α含量显著下降,说明本次测试阳性对照有效。
与NC组相比,样品精华液的IL-1α含量显著下降,抑制率为38.46%。
TNF-α测试结果
与BC组相比,NC组的TNF-α含量显著上升,说明本次测试刺激条件有效。
与NC组相比,PC组的TNF-α含量显著下降,说明本次测试阳性对照有效。
与NC组相比,样品精华液的TNF-α含量显著下降,抑制率为60.66%。
PGE2测试结果
与BC组相比,NC组的PGE2含量显著上升,说明本次测试刺激条件有效。
与NC组相比,PC组的PGE2含量显著下降,说明本次测试阳性对照有效。
与NC组相比,样品精华液的PGE2含量显著下降,抑制率为53.79%。
(3)修护功效
①测试原理:本测试采用600mJ/cm2UVB刺激3D表皮皮肤模型通过检测待测样品作用皮肤模型后的经表皮失水率(TEWL)的变化,评价待测样品的修护功效。皮肤组织受到外界刺激后会损伤皮肤屏障,经表皮失水率(Trans-EpidermalWaterLoss,TEWL),又称透皮失水率,是指经过表皮,在单位时间内流失水分的速度。TEWL越大,表示单位时间内流失的水分越多,皮肤受损。因此,本实验以3D表皮皮肤模型为测试工具,通过检测待测样品作用皮肤模型后的经表皮失水率(TEWL)含量的变化,评价待测样品的修护功效。
②测试系统:本次测试所用3D表皮皮肤模型批号:ES230101,由广东博溪生物科技有限公司提供。主要试剂EpiGrowth培养液(广东博溪生物)、PBS(索莱宝)、WY14643(Sigma)。主要设备CO2培养箱(Thermo,150I)、超净工作台(苏净安泰,SW-CJ-1F)、TEWL值测量探头(Courage+Khazakaelectronic,/>TW24)。
③测试分组及结果
与BC组相比,NC组的经表皮失水率(TEWL)显著上升,说明本次测试刺激条件有效。
与NC组相比,PC组的经表皮失水率(TEWL)显著下降,说明本次测试阳性对照有效。
与NC组相比,样品一页婴童舒缓特护精华露的经表皮失水率(TEWL)显著下降,下调率为21.52%
综上,精华液在3D皮肤模型测试表现出高效的保湿、舒缓、修护效果。
4、精华液的人体功效临床试验
在正常情况下,通过成年受试者按照说明连续使用产品14天,评估该产品是否具有保湿、舒缓、修护的功效。完成评估有效人数共31人,敏感皮肤(乳酸刺痛筛选)中国女性,年龄20至59岁;评估区域为面部;使用方法为用指腹按压泵头取适量本品于掌心,均匀涂抹于面部,轻揉按摩至吸收;使用周期14天;评估周期为使用产品前(D0)、使用产品30分钟后(D0_T30min),使用产品14天后(D14)。其中包括:利用Visia-CR进行的面部图像检测、利用IPP软件分析Visia-CR图片测定皮肤红色区a值、利用MX18进行皮肤血红素检测、利用皮肤颜色测定仪ColorimeterCL400检测皮肤颜色、利用皮肤水分流失测定仪/>TMHex检测皮肤经表皮失水率、利用皮肤水分测定仪/>CM825检测皮肤水分含量和受试者自我评估等。
(1)皮肤泛红
分析值变小说明皮肤泛红有改善。*表示与使用产品前相比,使用产品后测量值有显著性差异,结果见图1-图4。
与使用产品前相比:
使用产品30分钟后,脸颊分析区域皮肤红区a*值显著性减少7.67%,红区面积占比显著性减少21.61%。
使用产品14天后,脸颊分析区域皮肤红区a*值显著性减少14.38%,红区面积占比显著性减少39.30%。
(2)皮肤血红素含量
测量值变小,说明皮肤血红素含量减少。表示与使用产品前相比,使用产品后测量值有显著性差异。
使用产品30分钟后,脸颊分析区域皮肤血红素含量显著性减少8%;
使用产品14天后,脸颊分析区域皮肤血红素含量显著性减少10.45%。
(3)皮肤颜色
皮肤颜色L*值越大说明皮肤越亮;皮肤颜色a*值越小说明皮肤颜色越不红。
与使用产品前相比:
使用产品30分钟后,脸颊测试区域皮肤经皮水分流失率显著性减少11.48%;
使用产品14天后,脸颊测试区域皮肤经皮水分流失率显著性减少10.12%。
综上结果表明:
(1)与使用产品前相比,使用产品30分钟后,使用产品14天后,皮肤角质层水分含量均有显著改善,评估在该评估条件下,产品具有保湿功效;
(2)与使用产品前相比,使用产品30分钟后,使用产品14天后,皮肤经皮水分流失率和皮肤角质层水分含量均有显著改善,评估在该评估条件下,产品具有修护功效;
(3)与使用产品前相比,使用产品30分钟后,使用产品14天后吗,皮肤红区a*值(图像分析)、皮肤红区面积占比(图像分析)和皮肤颜色a*值均有显著性改善,评估在该评估条件下,产品具有舒缓功效。
(4)使用产品期间,0例受试者出现局部或全身的皮肤不良反应,表明产品使用安全。
Claims (10)
1.一种保湿舒缓修护的高功效婴童护肤精华液,其特征在于,按质量份计,制备原料包括:0.5-3份舒缓组合物、5-12份保湿剂、0.1-1份乳化剂、0.1-0.8份肤感调理剂、85-120份水。
2.根据权利要求1所述的精华液,其特征在于,所述舒缓组合物选自植物提取物、天然油脂、倍半萜烯醇、水解蛋壳膜、羟苯基丙酰胺苯甲酸、维生素C及其衍生物中的一种多种。
3.根据权利要求2所述的精华液,其特征在于,所述植物提取物选自西班牙鼠尾草籽提取物、甘草酸二钾、积雪草提取物、马齿苋提取物中的一种或多种。
4.根据权利要求3所述的精华液,其特征在于,所述天然油脂选自蛋黄油、鱼油、蓖麻油、椰子油、杏仁油、葡萄籽油、荷荷巴油中的一种或多种。
5.根据权利要求4所述的精华液,其特征在于,所述倍半萜烯醇选自檀香醇、红没药醇、岩兰草醇、金合欢醇中的一种或多种。
6.根据权利要求1-5任一项所述的精华液,其特征在于,所述保湿剂选自醇类、氨基酸、糖类、矿脂中的一种或多种。
7.根据权利要求6所述的精华液,其特征在于,所述肤感调理剂选自油脂、淀粉、植物多糖中的一种或多种。
8.根据权利要求7所述的精华液,其特征在于,所述油脂为辛酸/癸酸甘油三酯、PEG-7甘油椰油酸酯、抗坏血酸棕榈酸酯的组合,质量比为(0.001-2):(0.001-2):(0.00005-2)。
9.根据权利要求7或8所述的精华液,其特征在于,按质量份计,制备原料还包括:0.8-1.5份防腐剂、0.05-0.5份增稠剂。
10.一种根据权利要求9所述的精华液的制备方法,其特征在于,包括以下步骤:常温下将水加入水锅,撒入乳化剂,分散至均匀,然后加入醇类、增稠剂搅拌加热至80-85℃,搅拌至物料完全溶解后开启降温,降温至40-50℃时,加入氨基酸、甘草酸二钾,搅拌至料体均一;开启均质,加入蛋黄油、红没药醇、辛酸/癸酸甘油三酯,3000-4000r均质4-6min,搅拌至料体均一;加入糖类保湿剂、西班牙鼠尾草籽提取物、水解蛋壳膜、羟苯基丙酰胺苯甲酸、抗坏血酸棕榈酸酯、PEG-7甘油椰油酸酯、防腐剂搅拌均匀,真空脱泡,过滤出料,即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310500647.XA CN116473903A (zh) | 2023-05-05 | 2023-05-05 | 一种保湿舒缓修护的高功效婴童护肤精华液及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310500647.XA CN116473903A (zh) | 2023-05-05 | 2023-05-05 | 一种保湿舒缓修护的高功效婴童护肤精华液及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116473903A true CN116473903A (zh) | 2023-07-25 |
Family
ID=87211749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310500647.XA Pending CN116473903A (zh) | 2023-05-05 | 2023-05-05 | 一种保湿舒缓修护的高功效婴童护肤精华液及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116473903A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117045565A (zh) * | 2023-10-12 | 2023-11-14 | 广州科玛生物科技股份有限公司 | 一种婴幼儿舒缓保湿面霜及其制备方法和应用 |
-
2023
- 2023-05-05 CN CN202310500647.XA patent/CN116473903A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117045565A (zh) * | 2023-10-12 | 2023-11-14 | 广州科玛生物科技股份有限公司 | 一种婴幼儿舒缓保湿面霜及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109846757B (zh) | 一种皮脂仿生组合物及包含其的化妆品 | |
EP3436158B1 (en) | Topical composition comprising plant extracts | |
KR20180036580A (ko) | 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물 | |
JP2008195734A (ja) | 皮膚加齢の徴候を処置するための組成物 | |
CN110691630A (zh) | 红毛丹果皮提取物在皮肤和/或粘膜保湿中的用途 | |
KR101500191B1 (ko) | 피부 케어용 조성물 및 이의 제조 방법 | |
CN116473903A (zh) | 一种保湿舒缓修护的高功效婴童护肤精华液及制备方法 | |
JP2010520232A (ja) | 玄参抽出物を含有する外用剤組成物及びその皮膚保湿化粧料としての用途 | |
US10933103B2 (en) | Dermatologic composition containing Escherichia coli and Enterococcus faecalis | |
US20150118334A1 (en) | Topical compositions for the treatment of chronic inflammatory skin disease | |
WO2013190542A2 (en) | Topical compositions for the treatment of chronic inflammatory skin disease | |
KR101857282B1 (ko) | 패 추출물을 포함하는 화장료 조성물 | |
EP3040105B1 (fr) | Utilisation cosmetique d'un extrait de baies de rosa canina particulier comme actif anti-seborrhee | |
CN110974716B (zh) | 一种预防和治疗妊娠纹的组合物 | |
FR2831058A1 (fr) | Composition cosmetique hydratante comprenant des aquaporines | |
KR20160020038A (ko) | 프랜지패니 오일 또는 프랜지패니 오일의 발효물을 포함하는 화장료 조성물 | |
CN115813826B (zh) | 一种紧致抗皱组合物及其在化妆品中的应用 | |
US20230309921A1 (en) | Window of Opportunity Skin Treatment Regimen and Composition for Preventing the Onset of or Treating Atopic Dermatitis | |
CN116473864A (zh) | 一种小分子肽多维透皮方法及其应用 | |
TWI491404B (zh) | New use of hesperetin | |
CN116492237A (zh) | 一种降低表面活性剂刺激性的组合物及其应用 | |
KR20230037965A (ko) | 피부장벽 형성인자를 유효성분으로 포함하는 보습 및 진정용 화장료 조성물 | |
CN115607482A (zh) | 一种舒缓保湿乳液及其制备方法 | |
WO2023161293A1 (fr) | Composition cosmétique lipidique destinée à être intégrée dans une composition cosmétique de soin de la peau et des fibres kératiniques | |
Matysiak et al. | STUDIES ON THE FORMULATION AND FUNCTIONALITY OF AN INNOVATIVE LINE OF TOPICAL PRODUCTS FOR ATOPIC SKIN. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |